Transaction · 0001601830-25-000019

Taylor Ben R

Taylor Ben R, CFO, reported a transaction classified as withholding at RECURSION PHARMACEUTICALS, INC. involving 10879.000000 shares for an estimated $115752.56. Reported holdings after the transaction were 875727.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

withholdingSEC transaction code FCFO
RXRXRECURSION PHARMACEUTICALS, INC.
Filing timeFeb 20
Trade dateFeb 18, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
Pre-filing
Returns since

RXRX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
RXRX since 2025-02-20Filed 561 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
withholding
Code F
Identifier
0001601830-25-000019
Class A Common Stock
Transaction date
Feb 18, 2025
Filed Feb 20, 2025, 09:42 PM · 2d delay
Shares
10.8k sh
$1.06k per share
Estimated value
-$11.5M
Computed from shares × price
Holdings after
875k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
-12score
Filing-only score

-12

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

  2. F2

    The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter…

  3. F3

    Twenty-five percent of the shares subject to the award vest and become exercisable on November 17, 2021, and the remaining shares subject to the award vest and become exercisable in annual installment…

  4. F4

    Twenty-five percent of the shares subject to the award vest and become exercisable on April 3, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments…

  5. F5

    Twenty-five percent of the shares subject to the award vest and become exercisable on July 1, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments…

  6. F6

    1/48th of the shares subject to the award vests and become exercisable on January 2, 2025, and each month thereafter, subject to Mr. Taylor's continued service through each vesting date.

Original filing · 0001601830-25-000019
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

RXRX